Program
milvexian
Also written as “BMS-986177”, “Milvexian” and “JNJ-70033093”.
Its studies are mostly in Thrombosis · Ischemic Stroke · Atrial Fibrillation · Acute Coronary Syndrome · Stroke, led by 2 companies.
Drug pageMilvexian: every studyAll 25 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibbits history only | 140 open or running | phase 2since Dec 20, 2016 | Nov 17, 2015 | none ahead |
| Johnson & Johnsonits history only | 112 open or running | phase 3since Jan 19, 2023 | Mar 25, 2019 | Dec 8, 2026phase 3 · NCT05757869 |
- Named in Bristol-Myers Squibb’s own pipeline as
milvexian
, phase 3, as of Oct 29, 2026 (source). - Named in Johnson & Johnson’s own pipeline as
milvexian
, phase 3, as of Oct 13, 2026 (source).
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- Co-developmentJanssen (Johnson & Johnson) develops it with Bristol Myers Squibb, worldwide, development costs and profits shared.Announced Apr 16, 2018 · Source: Johnson & Johnson, Apr 16, 2018
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 10 studies since Nov 17, 2015.
- Apr 16, 2018Janssen (Johnson & Johnson) develops it with Bristol Myers SquibbCo-developmentWorldwide, development costs and profits shared · announced · Johnson & Johnson
- Oct 4, 2018Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT03698513 · 113 enrolled · United States
- Nov 13, 2018Phase 2 study in Ischemic StrokeBristol-Myers Squibb · NCT03766581 · 2,366 enrolled · United States, Argentina, Australia and more
- Mar 25, 2019Johnson & Johnson’s first study: phase 2 study in Arthroplasty, Replacement, KneeNew to Johnson & JohnsonJohnson & Johnson · NCT03891524 · 1,242 enrolled · United States, Argentina, Belgium and more
- May 2, 2019Phase 1 study in ThrombosisBristol-Myers Squibb · NCT03939702 · 9 enrolled · United States
- Dec 18, 2019Phase 1 study in HealthyJohnson & Johnson · NCT04206488 · 30 enrolled · Belgium
- Jan 8, 2020Phase 1 study in HealthyJohnson & Johnson · NCT04223349 · 66 enrolled · United States
- May 12, 2020Phase 1 study in HealthyJohnson & Johnson · NCT04388501 · 23 enrolled · Belgium
- Jun 9, 2020Named milvexianINNProposed as its International Nonproprietary Name in WHO's List 123 · before, BMS-986177, JNJ-70033093
- Jun 25, 2020Phase 1 study in HealthyJohnson & Johnson · NCT04448964 · 24 enrolled · Belgium
- Sep 11, 2020Phase 1 study in HealthyJohnson & Johnson · NCT04569695 · 40 enrolled · China
- Apr 12, 2021Phase 1 study in HealthyJohnson & Johnson · NCT04844424 · 115 enrolled · United States
- Jul 7, 2021Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT04965389 · 17 enrolled · United Kingdom
- Jan 19, 2023Phase 3 study in Ischemic StrokeJohnson & Johnson · NCT05702034 · 12,523 enrolled · United States, Argentina, Australia and more
- Jan 23, 2023Phase 1 study in Healthy FemaleJohnson & Johnson · NCT05706753 · 20 enrolled · Belgium
- Feb 23, 20232 phase 3 studiesJohnson & Johnson · NCT05754957, NCT05757869
Ahead
- Dec 8, 2026Primary completion: phase 3 study in Atrial FibrillationJohnson & Johnson · NCT05757869
TargetBeta
“A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants With Atrial Fibrillation”study text, read by Claude · the study
Other programs on F11
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| abelacimab | anthos-therapeutics-inc | phase 3 | 8 |
| SHR-2004 | Jiangsu HengRui Medicine | phase 3 | 5 |
Studies
All 25 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT05757869Atrial Fibrillation · United States, Argentina, Australia and more | 3 | Active, not recruiting | Johnson & Johnson | Dec 8, 2026 | 20,284 |
| NCT05754957Acute Coronary Syndrome · United States, Argentina, Australia and more | 3 | Completed | Johnson & Johnson | Feb 6, 2026 | 14,194 |
| NCT05706753Healthy Female · Belgium | 1 | Completed | Johnson & Johnson | Jul 20, 2023 | 20 |
| NCT05702034Ischemic Stroke · United States, Argentina, Australia and more | 3 | Active, not recruiting | Johnson & Johnson | Oct 15, 2026 | 12,523 |
| NCT04965389Healthy Volunteers · United Kingdom | 1 | Completed | Bristol-Myers Squibb | Aug 22, 2021 | 17 |
| NCT04844424Healthy · United States | 1 | Completed | Johnson & Johnson | May 6, 2022 | 115 |
| NCT04569695Healthy · China | 1 | Completed | Johnson & Johnson | Dec 4, 2021 | 40 |
| NCT04448964Healthy · Belgium | 1 | Completed | Johnson & Johnson | Nov 14, 2020 | 24 |
| NCT04388501Healthy · Belgium | 1 | Completed | Johnson & Johnson | Oct 25, 2021 | 23 |
| NCT04223349Healthy · United States | 1 | Completed | Johnson & Johnson | Apr 8, 2020 | 66 |
| NCT04206488Healthy · Belgium | 1 | Completed | Johnson & Johnson | Jun 9, 2021 | 30 |
| NCT03939702Thrombosis · United States | 1 | Completed | Bristol-Myers Squibb | Jul 11, 2019 | 9 |
| NCT03891524Arthroplasty, Replacement, Knee · United States, Argentina, Belgium and more | 2 | Completed | Johnson & Johnson | Apr 6, 2021 | 1,242 |
| NCT03766581Ischemic Stroke · United States, Argentina, Australia and more | 2 | Completed | Bristol-Myers Squibb | Mar 31, 2022 | 2,366 |
| NCT03698513Healthy Volunteers · United States | 1 | Completed | Bristol-Myers Squibb | Feb 19, 2019 | 113 |
| NCT03362437Thrombosis · United Kingdom | 1 | Completed | Bristol-Myers Squibb | Dec 28, 2017 | 12 |
| NCT03341390Stroke · United States | 1 | Completed | Bristol-Myers Squibb | Nov 16, 2017 | 20 |
| NCT03224260Thrombosis · United States | 1 | Completed | Bristol-Myers Squibb | Nov 7, 2017 | 33 |
| NCT03196206Thrombosis · United States | 1 | Completed | Bristol-Myers Squibb | Mar 4, 2018 | 24 |
| NCT03000673Antithrombotic · United States | 2 | Completed | Bristol-Myers Squibb | Oct 23, 2017 | 32 |
| NCT02982707Thrombosis · United States | 1 | Completed | Bristol-Myers Squibb | Sep 28, 2018 | 26 |
| NCT02959060Thrombosis | 1 | Completed | Bristol-Myers Squibb | Dec 2016 | 16 |
| NCT02902679Thrombosis · United States | 1 | Completed | Bristol-Myers Squibb | Jun 2017 | 6 |
| NCT02807909Thrombosis | 1 | Completed | Bristol-Myers Squibb | Aug 2016 | 28 |
| NCT02608970Thrombosis · Belgium | 1 | Completed | Bristol-Myers Squibb | Jul 23, 2017 | 104 |
How it is read
Names in the registry
- “BMS-986177”, 14 entries
- “Milvexian”, 6 entries
- “JNJ-70033093”, 4 entries
- “JNJ-70033093 25 mg”, 1 entry
- “JNJ-70033093 50 mg”, 1 entry
Conditions, from the studies’ own filings
- Thrombosis, 9 studies
- Ischemic Stroke, 2 studies
- Atrial Fibrillation, 1 study
- Acute Coronary Syndrome, 1 study
- Stroke, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.